Rapido

Quick links to important sections

Rapido

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rapido

Property Description
Active ingredient Fexofenadine Hydrochloride
Form Oral film-coated tablet
Pharmacological class Second-generation H1 Antihistamine
Common purpose Symptomatic relief of allergic conditions
Origin Synthetic compound

What is Rapido and its Active Composition?

Rapido is a modern anti-allergic medicine defined by its active pharmaceutical ingredient, the synthetic compound Fexofenadine Hydrochloride. This product is classified as a non-sedating remedy designed to counteract the body's reaction to common allergens. It is a single-ingredient product supplied in the form of an oral tablet that is film-coated, intended for ingestion.

The identity of the medicine is centered entirely on Fexofenadine Hydrochloride, a compound recognized for its action against allergy symptoms. The drug is focused on the anti-histamine mechanism. It is administered via the oral route, a delivery method intended for efficient systemic absorption, as the chemical structure of Fexofenadine is engineered to maximize therapeutic selectivity.

What Pharmacological Class Does Rapido Belong To?

Rapido belongs to the second-generation antihistamine pharmacological class, functioning as a highly selective peripheral H1 receptor antagonist. This classification means the medicine works by targeting and blocking the effects of histamine at receptor sites located primarily outside the central nervous system. Fexofenadine is categorized as a systemic anti-allergic agent.

The drug's core mechanism is the interruption of the allergic response cascade. By occupying H1 receptors, Fexofenadine prevents histamine from binding, thereby providing symptomatic relief for allergic conditions, such as those caused by seasonal environmental factors. This specific action is what distinguishes the second-generation class, allowing it to manage allergic symptoms without the sedative effects typically associated with older antihistamines.

Regulatory References

  1. Fexofenadine - StatPearls - NCBI Bookshelf

What side effects are possible with Rapido?

Possible Side Effects and Safety Information

The safety profile of Rapido (Fexofenadine Hydrochloride) is officially documented by regulatory authorities, classifying possible effects by frequency and system-organ class.


Adverse Reactions Classified by Frequency

Official labels detail adverse events observed in clinical trials and post-marketing experience. Common reactions reported include headache, drowsiness, dizziness, nausea, and fatigue. Reactions like insomnia and nervousness are generally considered uncommon.


Serious Adverse Reactions

The regulatory safety profile highlights the potential for rare, but clinically important, reactions, typically identified through post-marketing surveillance. These include serious systemic hypersensitivity reactions such as Angioedema (swelling), Dyspnoea (difficulty breathing), and Systemic Anaphylaxis. Additionally, the development of tachycardia (fast heart rate) and palpitations has been noted in the safety documentation.


Specific Safety Considerations

The official label contains specific safety statements concerning certain patient groups. Caution is noted for patients with renal impairment due to documented increases in Fexofenadine plasma concentrations. Similarly, older adults are advised to use the drug with caution due to limited clinical experience in this population. The use of Fexofenadine during pregnancy and lactation should be considered in light of limited available human data.


Regulatory Restrictions

The medicine is formally contraindicated in individuals with known hypersensitivity to Fexofenadine Hydrochloride or any of the product’s excipients. Furthermore, the label notes that the absorption of the medicine may be reduced when taken simultaneously with certain fruit juices (such as grapefruit, apple, or orange) or with aluminum- or magnesium-containing antacids, a high-level safety constraint.

Overdose and Emergency Response

The official regulatory documentation on Rapido (Fexofenadine Hydrochloride) overdose describes specific clinical manifestations and mandated emergency actions following ingestion volumes significantly exceeding the recommended dosage. Overdose presentations are documented to include symptoms such as dizziness, drowsiness (somnolence), fatigue, and dry mouth. Due to the potential for severe effects, particularly involving the cardiovascular system, assessment procedures include monitoring for complications like tachycardia and cardiac arrhythmia following large ingestions.

In the event of a suspected overdose, regulatory guidance requires immediate action. Individuals must seek emergency medical attention or contact the Poison Help line without delay. Urgent contact with emergency services is required if the person has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Management is officially described as providing symptomatic and supportive treatment, with standard measures to remove any unabsorbed drug. Regulatory documentation notes that a specific antidote is not known, and haemodialysis is not effective at removing the drug. Patients with renal impairment (kidney disease) are a specific consideration, as the drug's elimination half-life is prolonged, potentially increasing the severity of overdose effects.

Therapeutic Uses of Rapido

What Rapido Treats: Main Uses and Benefits

Rapido is commonly used in situations involving certain distressing symptoms of allergic conditions and is utilized in areas where short-term symptom management is appropriate.


Supportive Management of Seasonal and Environmental Allergy Symptoms

Rapido is commonly used across conditions presenting with acute or episodic manifestations of seasonal allergic rhinitis (hay fever). It helps manage symptom clusters that may become intense or disruptive, specifically sneezing, runny nose, and itching of the eyes or throat. Applied in clinical settings that involve acute symptom patterns, this medication contributes to improved comfort during periods of heightened symptoms associated with environmental allergens.


Supportive Management of Chronic Hives and Allergic Skin Itching

The medication is relevant in conditions characterized by recurrent or fluctuating manifestations, offering symptomatic support for Chronic Idiopathic Urticaria (hives). It is applied in addressing pronounced symptoms of skin discomfort, namely intense pruritus (itching) and the presence of hives. Rapido provides supportive relief when symptoms interfere with routine activities and assists with supporting functional stability during episodes where allergic skin manifestations are more noticeable.


Quick Fact: Focus on Pruritus and Hives

The active ingredient in Rapido is commonly used to help with symptomatic discomfort associated with two key domains: the upper respiratory and ocular discomfort of hay fever, and the dermal symptoms of allergic skin conditions like chronic hives.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Rapido — Official Regulatory Information

The official population eligibility for Rapido (Fexofenadine Hydrochloride) is strictly defined by regulatory authorities based on age, physiological state, and known hypersensitivity.


Eligibility Scope

Classification Population Rule Status
Absolute Contraindication Patients with known hypersensitivity to Fexofenadine Hydrochloride or any ingredient in the formulation. Prohibited
Age Restriction Infants under 6 months (for Hives) or children under 2 years (for seasonal allergies) are not approved for use in all jurisdictions. Not Established

Age and Condition-Specific Rules

  • Pediatric Use: The medicine is approved for adults and adolescents (ge 12 years). Approval extends to children down to age 2 years for seasonal allergies and 6 months for Chronic Idiopathic Urticaria (Hives), requiring age-appropriate formulations.
  • Renal Impairment: Use requires caution in patients with decreased kidney function. Regulatory documents recommend a dose adjustment for these patients and for older adults (ge 65 years) due to the greater likelihood of age-related decline in renal function.
  • Pregnancy and Lactation: Use during pregnancy is restricted to cases where the potential benefit justifies the potential risk, as adequate safety studies are lacking. Caution is advised when administering to a nursing mother.
  • Excipient Restriction: The orally disintegrating tablet (ODT) formulation is contraindicated for patients with Phenylketonuria (PKU) because it contains phenylalanine.

Connection to the overall eligibility profile: Regulatory documents define who can and cannot use the medicine by establishing explicit prohibitions (contraindications) and necessary precautions (conditional use) based on non-standard physiological states, ensuring all approved use is grounded in established safety criteria.

What should I know about interactions with other medicines?

Rapido Interactions with Other Medicines and Products

The interaction profile of Rapido (Fexofenadine Hydrochloride) is defined by its minimal hepatic metabolism and its dependence on drug transport systems for absorption and clearance, according to regulatory documentation.


Documented Interactions Modifying Drug Exposure

Interacting Substance Official Effect on Rapido Levels Mechanism Focus (as per label)
Ketoconazole & Erythromycin Significantly increased plasma concentrations ( C max and AUC). Inhibition of drug transporters (P-gp).
Antacids (Aluminium & Magnesium) Significantly decreased plasma concentrations. Physical binding in the digestive tract.
Apalutamide Documented decrease in total exposure (AUC). Induction of P-glycoprotein (P-gp) transporter.

Official Regulatory Constraints

Rapido's prescribing information includes specific requirements to manage these interactions, focusing primarily on administration timing and co-ingestion with beverages.

  • Timing Requirement: Antacids containing aluminium and magnesium hydroxide must not be taken at the same time as Rapido. A time separation between administrations (e.g., 15 minutes to 2 hours) is officially advised to avoid a reduction in Rapido's absorption.
  • Beverage Restriction: The label explicitly states that Rapido should be taken with water, not with grapefruit, orange, or apple juices. These fruit juices are documented to reduce the medication's systemic bioavailability.

Population-Specific Interaction Note

Regulatory documents note that the relevance of interactions and plasma exposure are increased in patients with renal impairment. The elimination half-life is prolonged, requiring careful consideration when co-administering interacting substances in this population.

Mechanism of Action

Mechanism of Action: How Rapido Works

Rapido is a pharmacological agent that exerts its effect through targeted receptor- or enzyme-mediated signaling within specific biological systems. Its mechanism involves a precise interaction with a defined molecular target, acting as a selective modulator of key intracellular signal transduction pathways.

This interaction initiates a downstream cascade where the drug modifies early molecular steps, altering the flux of specific transmitters and mediators. By influencing the concentration and duration of these signaling molecules, Rapido effectively changes the subsequent pathway activity. This engagement is crucial in systems where signaling processes exhibit elevated or altered activity. The resultant change in feedback regulation within these critical pathways directly influences systemic physiological output, leading to pathway adjustments that characterize the compound's pharmacodynamic effect profile.

Dosage and Administration Information

How to use Rapido: General Administration Guidelines


Administration and Dosage Regimens

Rapido, which contains Fexofenadine Hydrochloride, is administered via the oral route as a film-coated tablet. The tablet is intended to be swallowed whole with water and is not to be crushed, broken, or chewed. Standard adult dosing is typically either a 60 mg tablet taken twice daily (BID) or a 180 mg tablet taken once daily (QD).

Contextual Intake and Scheduling

Administration involves specific procedural constraints related to ingestion. While the tablets are taken with water, instructions for use indicate avoiding concurrent intake with fruit juices, such as grapefruit, orange, or apple juice. The frequency of use is categorized as a daily pattern, typically continuing for the duration of acute symptoms or as part of a long-term plan for chronic conditions. If a dose is missed, the schedule is resumed with the next dose at the usual time, without taking an extra amount.

Population-Specific Adjustments

Specific dose adjustments apply to certain patient populations. For adults and adolescents (aged 12 years and older) who have impaired kidney function, the dose is reduced to 60 mg taken once daily. No corresponding adjustment is indicated for patients with hepatic (liver) impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Rapido (Fexofenadine Hydrochloride)

Research Evidence for Seasonal Allergic Rhinitis (SAR)

Rapido was studied for its use in managing symptoms of seasonal allergic rhinitis, commonly known as hay fever. The primary research relies on short-term Randomized Controlled Trials (RCTs). These studies typically compare the medicine against an inactive substance (placebo). Researchers mainly measured the Total Symptom Score (TSS), tracking changes in specific physical discomforts like sneezing, runny nose, and itchy eyes. Research also examined patient-reported outcomes reflecting daily functioning or activity level.

Studies reported measurements of Total Symptom Scores that reflected differences between the observed treatment group and the placebo group over short evaluation periods. Studies monitored the changes in specific symptoms, such as sneezing and pruritus (itching), noting patterns in symptom scores that researchers tracked across the evaluation period. This body of evidence contributes to the broader evidence landscape regarding short-term symptom patterns in populations with conditions characterized by fluctuating or episodic manifestations.


Research Evidence for Chronic Idiopathic Urticaria (CIU)

Rapido was evaluated in studies addressing Chronic Idiopathic Urticaria (CIU), a condition marked by recurrent hives and intense itching. The research structure primarily involves intermediate-term Randomized Controlled Trials that were applied in studies examining chronic hives. These trials examined outcomes related to physical discomfort, focusing on reducing the severity of pruritus (itching) and the number of wheals (hives). Research also explored outcomes reflecting daily functioning.

Findings describe patterns observed over the intermediate-term duration of these studies, where symptom scores measured were tracked against the scores reported by the placebo groups. Trials consistently reported measurements of daily pruritus severity scores and wheal counts across the 4–6 week study duration. Reported outcomes described patterns in functional scores that tracked changes in the disruption to sleep and daily activities when compared to baseline. The consolidated body of research is graded as High-level, supported by multiple controlled studies consistently monitoring changes in these specific outcomes.


What Research Gaps and Uncertainty Remain

Clinical studies for Rapido mainly focused on acute or short-term changes in symptoms. For both allergic rhinitis and chronic hives, the follow-up durations were limited, typically spanning only a few weeks. The available research examined outcomes related to systemic or functional imbalance during periods of heightened symptom activity, but evidence is limited when assessing long-term symptom patterns across an entire year or over multiple seasons. Therefore, the long-term effects are not fully established.

Data for certain groups remain insufficient. For instance, older adults with multiple health conditions (comorbidities) and very young children have been less frequently included in the primary efficacy studies. Comparative evidence is lacking in specific settings; for example, not every study has directly compared this medicine to similar non-sedating antihistamines using identical designs and populations.

Key Studies & References

  1. Assessment of the Antiobstructive Effect of Fexofenadine on Nasal Allergy Challenge in Patients with Seasonal Allergic Rhinitis

Frequently Asked Questions (FAQ)

Common questions about Rapido (FAQ)


Q: Is Rapido considered a new type of medicine?

Rapido is officially classified as a second-generation H1 receptor antagonist. This pharmacological classification means it selectively targets H1 receptors located primarily outside the central nervous system. This specific mechanism is what distinguishes it from older antihistamine classes.


Q: How quickly does Rapido typically start to work?

Official studies indicate the onset is measurable in a short timeframe. The antihistamine effect was typically observed within one hour after taking a dose. Symptom score reductions have been noted to begin as early as 60 minutes after administration.


Q: Is it common to feel tired when first starting Rapido?

According to regulatory documents, reactions like drowsiness and fatigue are listed as common side effects reported by patients. However, official information does not specify whether these effects are more likely to occur only when an individual first starts using the medicine.


Q: How is Rapido different from other medicines used for similar conditions?

The medicine is characterized as a second-generation antihistamine. Official sources describe its key difference from older classes as its selective targeting of H1 receptors primarily outside the central nervous system. This selectivity is associated with minimal effects on the brain.


Q: How long do the effects of Rapido usually last?

Studies support Rapido's use on a once- or twice-daily schedule, based on the required daily schedule. The antihistamine effects have been shown to be maintained for at least 12 hours following a single standard dose, which aligns with the defined administration frequency.


Q: Does Rapido affect the ability to drive or operate machinery?

Objective safety tests indicate that Rapido does not produce significant effects on the central nervous system, meaning it is considered unlikely to affect driving ability. However, official guidance states that individuals should observe their personal response to the medicine before operating machinery or driving a vehicle.


Q: What happens if Rapido is taken longer than recommended?

Studies have examined chronic use of Rapido, even at high doses for up to one year in healthy adults. These studies indicated that continuous use did not result in clinically significant adverse reactions when compared against a placebo (inactive substance).


Q: Are there any reported interactions between Rapido and alcohol?

Official guidance notes that concurrent use of Rapido with alcohol is generally not recommended. Although the medicine is typically non-sedating, the combination with alcohol may increase the likelihood of experiencing drowsiness.


Q: Does Rapido need to be taken at a specific time of day?

The official administration instructions define a schedule of either once daily (QD) or twice daily (BID). The product label does not mandate a specific time of day, but maintaining a consistent daily schedule is supported by the administration instructions.


Q: Can Rapido be used alongside common pain relievers?

Regulatory information generally indicates that Rapido can be co-administered with common over-the-counter pain relievers, such as paracetamol and ibuprofen. Official documents have not reported a direct interaction between Rapido and ibuprofen.


Q: Is there a generic version of Rapido available?

The core component of Rapido is the active ingredient, Fexofenadine Hydrochloride, which serves as the non-proprietary or generic name for the medicine. Therefore, the product is available under both the brand name Rapido and under its generic name.


Q: What official regulatory bodies have approved Rapido?

The active ingredient in Rapido is subject to approval and ongoing monitoring by major governmental regulatory bodies worldwide. These authorities include the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


Q: Does Rapido interact with common medications for high blood pressure?

Regulatory information suggests that Rapido does not have specific listed interactions with common medications used to manage high blood pressure. Caution is noted only when Rapido is used in combination with a decongestant product.


Q: Is Rapido considered a high-risk medication?

Safety reviews indicate that the overall profile of Rapido is supported by clinical data. The medicine is generally associated with a low occurrence of side effects, although official information includes guidance regarding monitoring for rare symptoms such as fast or irregular heartbeat.


Q: Is Rapido available over the counter, or does it require a prescription?

The status of Rapido (Fexofenadine Hydrochloride) varies across jurisdictions. Depending on regulatory category and the age of the intended user, the medicine is available both as a prescription product and as an over-the-counter (OTC) medication in many areas.


Q: What patient groups are excluded from using Rapido based on clinical trials?

Clinical studies supporting the primary uses of Rapido focused mainly on adult and adolescent populations. Official documents indicate that the evidence base is limited for two specific patient groups: older adults with multiple pre-existing health conditions, and very young children. These groups were less frequently included in the core efficacy studies.


Q: Are there reports of Rapido interacting with over-the-counter cold medicines?

Official information notes a need for caution regarding co-administration of Rapido with over-the-counter cold medicines. This warning applies particularly to combination cold products, as they may already contain an antihistamine and combining them with Rapido could result in redundant or excessive use of similar ingredients.

How should Rapido be stored and disposed of?

Storage and Disposal Requirements for Rapido

Rapido (Fexofenadine Hydrochloride) tablets must be stored at a controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The medicine must be protected from excessive moisture and kept in a closed container. Regulatory requirements state that the tablets should not be frozen and must be stored out of the sight and reach of children.

Disposal

Expired or unused Rapido should not be flushed down the toilet or disposed of in wastewater. Official guidance recommends disposing of the product through an established drug take-back program. When no take-back option is available, unused product should be discarded according to local regulations after consulting a healthcare professional.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rapido found in:

A-Z Index: